Assessing the reporting quality of randomized controlled trials on COVID-19 vaccines: a systematic reviewCOVID-19 백신에 대한 무작위 대조 시험의 보고 품질 평가: 체계적인 검토Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] 임상, [키워드] adverse effect Analysis analysis of variance Assessing CONSORT CONSORT statement controlled trials COVID-19 COVID-19 vaccine COVID-19 vaccines criteria current database effective evaluated Evidence groups independent indicate indicated median Mortality no significant difference predicted Randomized Randomized controlled trial Randomized controlled trials RCT RCTs reported Reporting Reporting quality review. Standard systematic review Univariate analysis variance variety [DOI] 10.1080/21645515.2022.2031453 PMC 바로가기 [Article Type] Article
Quantifying the relationship between sub-population wastewater samples and community-wide SARS-CoV-2 seroprevalenceArticle Published on 2022-12-202022-11-15 Journal: The Science of the total environment [Category] COVID19(2023년), SARS, 진단, [키워드] Analysis assessment average Community Concentration conducted convenience sampling correlated correlation COVID-19 Disease prevalence Epidemic epidemiological Epidemiology estimate Health incidence rate increase in indicate Infection inherent biases Participants Prevalence prevalence rate Randomized regression analysis robust SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 seroprevalence serological sewer Spread stratified Stratified randomized sampling the disease USA Wastewater-based epidemiology. [DOI] 10.1016/j.scitotenv.2022.158567 PMC 바로가기
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Subunit vaccine. Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trialRandomized Controlled Trial Published on 2022-12-012022-10-05 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 임상, [키워드] antiseptic mouthwashe cell cultures cetylpyridinium chloride clinical trial COVID-19 COVID-19 patients Culture double-blind Effect evaluated Evidence in vitro in vivo indicated Infectivity Mouthwash mouthwashe mouthwashes not affected Placebo placebo-controlled clinical trial quantitative PCR Randomized reduce reduced reducing Saliva Saliva. salivary SARS-CoV-2 shown significantly tested viability viral infectivity Viral load Viral transmission virucidal [DOI] 10.1080/22221751.2022.2098059 PMC 바로가기 [Article Type] Randomized Controlled Trial
Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trialArticle Published on 2022-11-082022-11-16 Journal: Trials [Category] SARS, 변종, [키워드] adaptive anti-COVID-19 IVIG antivirals clinical evidence clinical trial collected convalescent convalescent plasma COVID-19 cumulative death Efficacy eligibility criteria evaluate Health hyperimmune immunization immunomodulators intravenous Intravenous immunoglobulin low dose monoclonal antibodies Neutralizing non-specific novel Novel coronavirus outcome Passive passive immunization Patient phase Pneumonia polyclonal polyclonal antibodies Pooled convalescent plasma Potential treatment Randomized Randomized controlled trial receive Recovered COVID-19 patients reported SARS CoV-2 SARS CoV-2. SARS-CoV-2 sealed Secondary outcomes severe COVID-19 severe COVID-19 patient severe COVID-19 patients Standard of care Steroids Study protocol therapeutic option therapy treat Treatment Trial variant variants of concern virus virus particles World Health Organization [DOI] 10.1186/s13063-022-06860-2 PMC 바로가기
Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trialArticle Published on 2022-11-032022-11-16 Journal: Journal of Translational Medicine [Category] 비임상, [키워드] 1:1 Administered administration adverse event age Analysis animal model Anti-inflammatory assigned baseline Borg change changes in Chronic diseases clinical trial clinically COVID COVID pneumonia COVID-19 defined Diagnosis discharged double-blind Dyspnea Effect effective Efficacy Endpoint enrolled evaluated female female gender FEV first symptom FVC impairment increase in indicated Infection initial LLC lung damage Lung fibrosis Lung function Lungs mMRC moderate NCT04527354 offer past medical history Patient patients pharmacological treatment Placebo placebo group placebo-controlled clinical trial placebo-controlled trial Post-COVID rehabilitation predicted Prevent Primary outcome proportion pulmonary dysfunction pulmonary fibrosis Pulmonary function questionnaire Randomized Randomly reduction in Registered rehabilitation risk factor Russia SARS-CoV-2 secondary shown significant decrease significant difference stratified Support Symptoms Tolerability Treamid. Treatment Trial was done women [DOI] 10.1186/s12967-022-03660-9 PMC 바로가기
Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trialArticle Published on 2022-11-012022-11-15 Journal: Intensive care medicine [Category] Fulltext, MERS, 바이오마커, [키워드] ABO-compatible convalescent plasma Adaptive platform trial Adults analysis assigned Biomarker Biomarkers chemokines community-acquired pneumonia convalescent plasma Convalescent plasma therapy coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient Critically ill critically ill patients Cytokines difference effector immune responses elevated endothelial explain heterogeneous homogeneous Hypothesis immunologically immunotherapies Inflammation IQR median multifactorial organ support outcome outcomes patients Population precision medicine Prevalence Randomized randomized clinical trial RCT RCTs REMAP-CAP reported secondary analysis Subphenotypes. tested therapy treatment effect Treatment response usual care with COVID-19 [DOI] 10.1007/s00134-022-06869-w PMC 바로가기
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trialArticle Published on 2022-11-012022-11-15 Journal: International Journal of Infectious Diseases [Category] 진단, [키워드] Administered adverse event age binding antibody clinical trial Comorbidities Comorbidity COVID-19 infection demonstrated dose double-blind elicited General population High dose High-dose immune response immunization immunogenicity immunosenescence Mild mortality rates MVC-COV1901 vaccine negative correlation Neutralizing Older older adult Older adults participant Phase 2 protein subunit vaccine Randomized regimen Registered robust Safety SARS-CoV-2. stratified subject Trial Vaccine [DOI] 10.1016/j.ijid.2022.08.021 PMC 바로가기
Efficacy of antiseptic mouthrinses against SARS-CoV-2: A prospective randomized placebo-controlled pilot studyArticle Published on 2022-11-012022-11-15 Journal: American journal of otolaryngology [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] Adult patients Affect analyzed baseline chlorhexidine clinical collected COVID-19 detectable Disinfection effective Effectiveness groups Hospitalized hydrogen peroxide individual initial mouth negativity oral oral cavity Oral diseases Oral medicine Oral rinses Patient pilot study Placebo placebo-controlled Povidone‑iodine Public public health Randomized recruited reduced reducing Replication Research Saliva. SARS-CoV-2 SARS-CoV-2 viral load swab specimens the placebo group viral copy number were measured [DOI] 10.1016/j.amjoto.2022.103549 PMC 바로가기